Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
We evaluate your current dietary intake, eating patterns, calorie expenditure, and level of physical activity
Mol Cell Endocrinol 436:240249
In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg
Hypokalemia: Rapid treatment of severe anaemia with vitamin B12 could cause low potassium levels (hypokalemia), necessitating monitoring
April 14, 2026
Shortages And Supply Chain Updates In 2025 For the past few years, drug shortages have been a major issue for patients trying to access GLP-1s
